newsfilter
← Latest News
ACCESS Newswire·

IGC Pharma CEO and Principal Financial Officer Purchase More Than $1.15 Million of Common Stock Directly from the Company

  • IGC Pharma CEO Ram Mukunda and CFO Claudia Grimaldi purchased 4,274,853 restricted common shares at $0.27 per share.
  • The transaction involved the cancellation of approximately $1.15 million in outstanding debts owed by the company to the executives.
  • The debt cancellation included over $552,362 in personal cash previously advanced to IGC by the two officers.
  • Mukunda received 2,226,475 shares in exchange for $601,148 in owed amounts, including $283,639 in personal advances.
  • Grimaldi received 2,048,378 shares in exchange for $553,062 in owed amounts, including $268,723 in personal advances.
  • The $0.27 share price matched the NYSE American closing price on June 29, 2026.
  • The shares were issued as restricted securities via a private placement exempt from registration under Section 4(a)(2) of the Securities Act of 1933.
  • Independent directors and the Audit Committee approved the transactions with the involved officers recused.
  • The executives received no preferred stock, warrants, liquidation preferences, or special voting rights.
  • IGC Pharma is a clinical-stage biotechnology company developing AI-enabled therapies for Alzheimer's disease.